The United Food and Commercial Workers Local 1500 Welfare Fund has filed an antitrust lawsuit against Johnson and Johnson in Pennsylvania’s Eastern District Court. The suit takes aim at the drug maker over its blockbuster innovator infliximab, Remicade.
The United Food and Commercial Workers Local 1500 Welfare Fund has filed an antitrust lawsuit against Johnson & Johnson in Pennsylvania’s Eastern District Court. The suit takes aim at the drug maker over its blockbuster innovator infliximab, Remicade.
The Pharma Letter reports that the union’s benefits fund has alleged anti-competitive behavior on Johnson & Johnson’s part. The complaint claims that the drug manufacturer has engaged in exclusionary contracting that is designed to maintain a monopoly on the US infliximab marketplace. The union, which represents grocery workers in the state of New York, seeks a jury trial over the drug maker’s contracting, rebate policies, and product bundling that it alleges are designed to block insurers from reimbursing for either of the 2 available biosimilar infliximab products, Inflectra and Renflexis.
The union is the second entity to challenge the reference drug sponsor in recent days; in September, Pfizer, maker of Inflectra, filed a district court lawsuit against Johnson & Johnson in the Eastern District of Pennsylvania. Pfizer alleged that Johnson & Johnson has effectively denied patients access to biosimilar therapies by threatening to withhold rebates from insurers unless they agree to exclude biosimilars from their formularies. The suit claims that as many as 70% of patients who have commercial insurance coverage are unable to gain access to Inflectra due to the drug maker’s conduct.
Johnson & Johnson said in a statement concerning the Pfizer case that “Competition is doing what competition is meant to do: driving deeper discounts that will lead to overall lower costs for infliximab, including [Remicade]. We stand by our contracts.” The reference infliximab sponsor added that “Rather than demonstrating value and working to win the trust of physicians and patients, Pfizer is asking the court to protect it from having to compete.”
Additionally, the company highlighted the fact biosimilars are not generics, and not identical to reference products. It suggested that, instead, Pfizer’s Inflectra is a new medicine that has not yet proven itself before physicians, payers, or patients.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.